Core Viewpoint - The report highlights the performance and management strategies of the AI Fund, specifically the China Europe Rui Da 6-Month Holding Mixed A Fund, which has shown modest growth in a challenging market environment [4][5]. Fund Performance - The fund reported a profit of 371,800 yuan in the fourth quarter, with a weighted average profit per fund share of 0.0144 yuan [4]. - The fund's net value growth rate for the reporting period was 0.85%, with a total fund size of 43.73 million yuan as of the end of the fourth quarter [4][15]. - As of January 21, the unit net value was 1.739 yuan, with a near-term performance of 2.00% over three months, 2.75% over six months, 4.82% over one year, and 12.29% over three years, ranking 329/630, 449/630, 487/630, and 263/570 respectively among comparable funds [5]. Market Analysis - The fund manager noted a transition in the bond market from "emotional recovery" to "prudent pricing" during the fourth quarter, influenced by a retreat in the equity market and a subsequent easing of redemption pressures on bond funds [4]. - The report indicates that the market experienced a brief recovery due to ample liquidity and a cleared trading structure, although concerns about future fiscal policies and supply-demand imbalances for long-term bonds led to a notable decline in long-end yields by year-end [4]. Investment Strategy - The fund's strategy involved reallocating some long-duration interest rate bonds to short-duration credit bonds to reduce duration while enhancing static returns [5]. - The fund maintained a flexible approach to managing convertible bond positions, participating in the market with a low overall position while anchoring around valuation centers [5]. Risk Metrics - The fund's three-year Sharpe ratio was 0.9492, ranking 114/541 among comparable funds [9]. - The maximum drawdown over three years was 2.41%, with the largest single-quarter drawdown recorded at 4.09% in the first quarter of 2021 [11]. Portfolio Composition - The average stock allocation over the past three years was 7.07%, significantly lower than the comparable average of 19.23%, with a peak allocation of 36.4% at the end of 2021 and a low of 5% at the end of 2025 [14]. - As of the end of the fourth quarter of 2025, the fund's top ten holdings included companies such as Taisheng Wind Power, Tonghua Dongbao, and Chengzhi Co., among others [17].

证券代码：600867 证券简称：通化东宝 公告编号：2026-007 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 641,362,975 股，占公司目前股份总额的 32.75%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 574,439,472 股，占 其及一致行动人所持有公司股份总额的 89.57%，占公司目前股份总额的 29.33%。 其中：东宝集团持有公司股份 619,500,796 股，占公司目前股份总额的 31.63%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 574,439,472 股， 占其所持有公司股份总额的 92.73%，占公司目前股份总额的 29.33%。 2026 年 1 月 16 日,本公司接到东宝集团关于股份解押及再质押相关情况 ...

Core Insights - COREE Company Limited has submitted its prospectus to the Hong Kong Stock Exchange, leveraging its position as China's largest pediatric pharmaceutical marketing service provider with exclusive distribution rights for key products like "Mami Ai" and "Yitanjing" [1][10] - The company has established a vast distribution network covering 31 provinces, reaching over 110,000 clinics and 310,000 pharmacies, aiming for a 15.9% market share in the pediatric pharmaceutical marketing service sector by 2024 [1][10] - Despite its strong market position, COREE faces challenges due to its heavy reliance on a few products from Hanmi Pharmaceutical, a declining newborn population, and increasing industry competition [1][11] Financial Performance - In the first half of 2025, COREE reported revenues of 1.006 billion yuan, a significant decline of 29.63% year-on-year, with net profit dropping by 62.59% to 107 million yuan [2][12] - The company's revenue structure shows that 90% of its income comes from pharmaceutical marketing, with 93% of that revenue concentrated in a few products sourced from Hanmi [2][12] - The newborn population in China has decreased from approximately 12 million in 2020 to about 9.54 million in 2024, directly impacting market demand for COREE's core pediatric products [2][12] Market Competition - In the probiotics segment, "Mami Ai" has fallen behind competitors like Shilian Kang and Yijunkang, with sales of 392 million yuan compared to 799 million yuan and 440 million yuan, respectively [3][13] - The market for COREE's flagship product "Yitanjing" in the children's cough and phlegm relief sector is also highly competitive, indicating that growth potential for core products may have peaked [3][13] Cash Flow and Financial Health - COREE's cash flow has become increasingly strained, with trade receivables rising from 53.26 million USD at the end of 2022 to 123 million USD by mid-2025, representing 67% of current assets [3][13] - The company has experienced a net outflow of cash from operating activities since 2024, with cash reserves declining from 26.12 million USD at the end of 2022 to 10.63 million USD by mid-2025 [4][14] - High customer concentration poses risks, with the largest customer accounting for 42.9% of revenue and the top five customers contributing 65.6% [4][14] R&D and New Business Development - COREE's R&D expenditure has remained low, with a rate of only 0.3%-0.6% from 2022 to mid-2025, and total R&D spending of just 760,000 USD in 2024 [5][15] - The company's own brand products lack competitive strength in the saturated maternal and infant market, leading to a 38% year-on-year decline in revenue from this segment in the first half of 2025 [6][15] Governance and Compliance Issues - COREE's governance structure is complicated by significant related-party transactions with Hanmi, which accounts for over 50% of procurement and more than 90% of sales revenue [8][17] - Historical compliance issues include unresolved regulatory approvals for a production facility, which could lead to penalties or operational disruptions [8][17] - The rationale for fundraising is questioned, especially given the low capacity utilization rates of production facilities, which have remained below 60% [9][18]

Group 1 - The core announcement is about the appointment of two new vice presidents, Guandong Liang and Fan Pu, at Tonghua Dongbao Pharmaceutical Co., Ltd. Their terms will last until the end of the current board's tenure [1][3] - Guandong Liang has extensive experience in the pharmaceutical industry, having held various positions in companies such as Shanghai Hengrui Medicine Co., Ltd. and Beijing Xuzheng Innovation Drug Research Institute [4][5] - Fan Pu has a strong background in finance, previously serving as a senior manager at China Resources Group and as CFO at Yuekang Pharmaceutical Group [4][6] Group 2 - The announcement also includes details about the share pledge and re-pledge by the controlling shareholder, Dongbao Industrial Group, which holds 641,362,975 shares, accounting for 32.75% of the total shares [8][9] - Dongbao Group has pledged 562,439,472 shares, which is 87.69% of their holdings and 28.72% of the total shares of the company [8][9] - The funds from the share pledge are primarily intended to supplement working capital, with no significant asset restructuring or performance compensation involved [10][12] Group 3 - Dongbao Group has upcoming share pledges due within the next six months and one year, totaling 98,000,000 shares and 115,500,000 shares respectively, with corresponding financing amounts of 39,500 million and 49,500 million [12][13] - The company asserts that the share pledges will not impact its operations or governance, and there are no performance compensation obligations to fulfill [12][18] - Dongbao Group's financial health is under scrutiny, with a high debt ratio and low liquidity ratios, but it is expected that ongoing projects will eventually improve cash flow [16][18]

Group 1 - The core point of the article is the appointment of two new vice presidents at Tonghua Dongbao, which was unanimously approved by the company's board of directors during its 21st meeting of the 11th session [2] - The newly appointed vice presidents are Mr. Guan Dongliang and Mr. Fan Pu, with their term starting from the date of the board's approval until the end of the current board's term [2] - This decision reflects the company's ongoing efforts to strengthen its leadership team [2]

Group 1 - The controlling shareholder of Tonghua Dongbao Pharmaceutical, Dongbao Industrial Group, and its concerted parties hold approximately 641 million shares, accounting for 32.75% of the company's total shares [1] - The total number of pledged shares by Dongbao Group and its concerted parties is about 562 million, representing 87.69% of their total holdings and 28.72% of the company's total shares [1] - Dongbao Group specifically holds around 620 million shares, which is 31.63% of the total shares, with a pledged amount of 562 million shares, making up 90.79% of its holdings and 28.72% of the company's total shares [1]

Group 1 - Company Tonghua Dongbao announced the appointment of Mr. Guan Dongliang and Mr. Fan Pu as vice presidents, following a proposal by the company's president and approval by the board of directors [1] Group 2 - The news highlights the potential introduction of a "budget version" of the Tesla Model 3 in the Chinese market, priced under 200,000 yuan, with a range of 480 kilometers [1] - There are significant adjustments in the U.S. market regarding autonomous driving technology [1]

证券代码：600867 证券简称：通化东宝 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 641,362,975 股，占公司目前股份总额的 32.75%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 562,439,472 股，占 其及一致行动人所持有公司股份总额的 87.69%，占公司目前股份总额的 28.72%。 其中：东宝集团持有公司股份 619,500,796 股，占公司目前股份总额的 31.63%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 562,439,472 股， 占其所持有公司股份总额的 90.79%，占公司目前股份总额的 28.72%。 2026 年 1 月 15 日,本公司接到东宝集团关于股份解押及再质押相关情况 ...

关于聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于 2026 年 1 月 15 日以通讯方式召开了第十一届董事会第二十一次会议，会议审议通过 了《关于聘任高级管理人员的议案》，本次会议应参加表决董事 9 人，实际参加 表决董事 9 人，符合《公司法》和公司章程的有关规定，所作决议合法有效。 根据公司发展需要，经公司总裁提名，董事会提名委员会审核通过，经与会 董事表决，一致同意聘任关东亮先生、范朴先生为公司副总裁，任期自本次董事 会审议通过之日起至第十一届董事会任期届满为止。 关东亮先生、范朴先生具备履行高级管理人员职责所必需的专业知识，相关 素养和工作经验，能够胜任高级管理人员的工作。关东亮先生、范朴先生的任职 资格符合《公司法》《上海证券交易所股票上市规则》《公司章程》等法律法规 的规定。 关东亮先生、范朴先生简历见附件。 特此公告。 通化东宝药业股份有限公司董事会 证券代码：600867 证券简称：通化东宝 公告编号：2026-005 通 ...

Core Viewpoint - The approval of the injectable type A botulinum toxin product from Huons BioPharma marks a significant milestone for the company, enhancing its strategic positioning in the competitive Chinese medical aesthetics market, which is characterized by a growing number of similar products [2][3]. Group 1: Company Developments - The company has been seeking new growth avenues beyond its core hyaluronic acid business, with the injectable botulinum toxin being one of its earliest product initiatives [2]. - The company signed an exclusive agency agreement with Huons Global in September 2018, which was later deepened by acquiring a 25.4% stake in Huons BP in June 2021 [3]. - The recent approval is expected to enrich the company's product matrix and allow for comprehensive solutions for clients, aligning with market expectations for product pricing and positioning [3][6]. Group 2: Market Context - The Chinese medical aesthetics market has seen significant changes over the past seven years, with the number of approved botulinum toxin products increasing to seven, including the newly approved product from Huons BP [7]. - The market was previously dominated by two brands, Botox and Hengli, which held a combined market share of 100% until recent years [7]. - The current market dynamics indicate that while new entrants may face challenges due to intense competition and price pressures, there is still potential for growth, particularly in the mid-to-high-end market segment [9]. Group 3: Stock Market Reaction - Following the announcement of the product approval, the company's stock price rose by 2.69%, reflecting positive market sentiment [5].